Gastroenterology: Lower serological responses to COVID-19 mRNA vaccine in patients with inflammatory bowel disease treated with anti-TNFα

COVID-19 ( new crown pneumonia ), which began to spread worldwide at the end of 2019, has caused a serious global medical challenge.
To cope with the huge morbidity and mortality burden, the world is accelerating vaccine development plans and large-scale vaccination.
vaccination campaign
.

Vaccine studies included healthy adults or adults with stable chronic disease, but with immune -mediated diseases such as inflammatory bowel disease (IBD), Crohn's disease (CD), andPatients with ulcerative colitis (UC) were explicitly excluded from the trial

COVID-19 ( new crown pneumonia ), which began to spread worldwide at the end of 2019, has caused a serious global medical challenge.

 

This is a prospective, controlled, multicenter cohort study conducted in Israel
.

The primary objective was to assess the serological response to the mRNA-based COVID-19 vaccine BNT162b2, as well as differences in kinetics, response predictors and safety, in IBD patients compared with HC

statistics

 

Overall, a total of 258 subjects were eligible for analysis in this study, including 185 with IBD (67 with anti-TNFα and 118 without anti-TNFα) and 73 with HC
.

After the first vaccination, all HCs were seropositive, while approximately 7% of IBD patients, regardless of treatment, remained seronegative

Figure: Schematic representation of anti-TNFα treatment in patients with inflammatory bowel disease

 

In this prospective study of IBD patients stratified by treatment, all patients had a serological response to 2 doses of BNT162b2; however, in patients receiving anti-TNFα therapy, regardless of timing of administration and drug level, Its magnitude is significantly reduced
.

The conclusion of this study is that the mRNA vaccine is safe, but booster doses should be considered due to the potentially limited lifespan of this vaccine serological response

In this prospective study of IBD patients stratified by treatment, all patients had a serological response to 2 doses of BNT162b2; however, in patients receiving anti-TNFα therapy, regardless of timing of administration and drug level, Its magnitude is significantly reduced

 

Original source:

Hadar Edelman-Klapper.

Lower Serologic Response to COVID-19 mRNA Vaccine in Patients With Inflammatory Bowel Diseases Treated With Anti-TNFα.
Leave a Comment